NVZMF:OTO-Novozymes A/S (USD)

COMMON STOCK | Specialty Chemicals | OTC Pink

Last Closing

USD 68.832

Change

-1.24 (-1.77)%

Market Cap

USD 11.39B

Volume

50.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novozymes A/S is a biotech company. The Company is engaged in research, development, production and selling enzymes and microorganisms.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-29 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap
AIQUY Air Liquide SA ADR

+0.12 (+0.29%)

USD 120.32B
AIQUF L'Air Liquide S.A

+0.32 (+0.15%)

USD 119.70B
GVDNY Givaudan SA ADR

+0.84 (+0.84%)

USD 44.92B
SXYAY Sika AG ADR

+0.04 (+0.13%)

USD 42.45B
GVDBF Givaudan SA

-37.41 (-0.75%)

USD 41.98B
SKFOF Sika AG

+0.13 (+0.05%)

USD 39.93B
DSFIY DSFIY

-0.01 (-0.09%)

USD 28.66B
DSMFF DSM-Firmenich AG

N/A

USD 28.44B
NPPHY Nippon Paint Holdings Co. Ltd.

+0.07 (+1.84%)

USD 17.49B
SYIEF Symrise AG

N/A

USD 16.28B

ETFs Containing NVZMF

MVAE:PA 0.74 % 0.00 %

N/A

N/A
MVAE:LSE 0.00 % 0.00 %

N/A

N/A
MVEX:LSE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Specialty Chemicals) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.47% 85% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.47% 85% B 73% C
Trailing 12 Months  
Capital Gain 10.79% 79% B- 65% D
Dividend Return 0.48% 6% D- 4% F
Total Return 11.27% 79% B- 63% D
Trailing 5 Years  
Capital Gain 27.47% 70% C- 64% D
Dividend Return 6.84% 13% F 15% F
Total Return 34.31% 65% D 61% D-
Average Annual (5 Year Horizon)  
Capital Gain -1.76% 46% F 39% F
Dividend Return 1.00% 53% F 41% F
Total Return 2.76% 71% C- 52% F
Risk Return Profile  
Volatility (Standard Deviation) 26.19% 72% C 76% C+
Risk Adjusted Return 3.81% 55% F 42% F
Market Capitalization 11.39B 93% A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector